Accelerating the Adoption of eSource in Clinical Research : A Transcelerate Point of View
For almost a decade, regulators and pharmaceutical industry groups have been interested in electronic source (eSource) in clinical trials (Nordo et al. in Learn Health Syst 3:e10076, 2019). eSource may provide efficiencies and value; however, eSource adoption is fragmented and slow. Acceleration of eSource adoption is a critical step in modernizing the conduct of clinical trials. The desired future state is one in which all source data, acquired through any context (e.g., healthcare delivery, chronic disease management) and actor (e.g., healthcare professional, patient, caregiver), are completely electronic, adequate in quality, and fully acceptable in clinical trial submissions by regulators worldwide. Achieving this desired future state requires transformative change management to foster adoption and minimize the burden of implementing eSource. Realizing this vision requires collaborative and dedicated efforts from multiple stakeholders, including patients, clinical trial participants, sites, technology vendors, standards organizations, regulators, payers, and sponsors. Stakeholders should align upon guidance to promote data integrity, data privacy, data security, and interoperability. The eSource revolution requires open dialogue, inclusive of shared learnings among stakeholders, to collectively and rapidly advance adoption. Adoption of eSource will optimize clinical research by enabling faster access to research data and more rapid decision-making, increasing clinical trial efficiency. Furthermore, adoption of eSource will improve data integrity by allowing direct data flow from the source to the sponsor's system, with minimal or no human intervention. This paper provides the TransCelerate point of view (POV) and recommendations to achieve the future state vision of complete utilization of eSource data in clinical trials and builds on previous TransCelerate eSource publications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Therapeutic innovation & regulatory science - 54(2020), 5 vom: 03. Sept., Seite 1141-1151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parab, Abhijit A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Applications |
|---|
| Anmerkungen: |
Date Completed 02.06.2021 Date Revised 02.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43441-020-00138-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307200345 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307200345 | ||
| 003 | DE-627 | ||
| 005 | 20231225125033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43441-020-00138-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1023.xml |
| 035 | |a (DE-627)NLM307200345 | ||
| 035 | |a (NLM)32128701 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parab, Abhijit A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accelerating the Adoption of eSource in Clinical Research |b A Transcelerate Point of View |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2021 | ||
| 500 | |a Date Revised 02.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a For almost a decade, regulators and pharmaceutical industry groups have been interested in electronic source (eSource) in clinical trials (Nordo et al. in Learn Health Syst 3:e10076, 2019). eSource may provide efficiencies and value; however, eSource adoption is fragmented and slow. Acceleration of eSource adoption is a critical step in modernizing the conduct of clinical trials. The desired future state is one in which all source data, acquired through any context (e.g., healthcare delivery, chronic disease management) and actor (e.g., healthcare professional, patient, caregiver), are completely electronic, adequate in quality, and fully acceptable in clinical trial submissions by regulators worldwide. Achieving this desired future state requires transformative change management to foster adoption and minimize the burden of implementing eSource. Realizing this vision requires collaborative and dedicated efforts from multiple stakeholders, including patients, clinical trial participants, sites, technology vendors, standards organizations, regulators, payers, and sponsors. Stakeholders should align upon guidance to promote data integrity, data privacy, data security, and interoperability. The eSource revolution requires open dialogue, inclusive of shared learnings among stakeholders, to collectively and rapidly advance adoption. Adoption of eSource will optimize clinical research by enabling faster access to research data and more rapid decision-making, increasing clinical trial efficiency. Furthermore, adoption of eSource will improve data integrity by allowing direct data flow from the source to the sponsor's system, with minimal or no human intervention. This paper provides the TransCelerate point of view (POV) and recommendations to achieve the future state vision of complete utilization of eSource data in clinical trials and builds on previous TransCelerate eSource publications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Applications | |
| 650 | 4 | |a Devices | |
| 650 | 4 | |a Direct data capture (DDC) | |
| 650 | 4 | |a Electronic health record (EHR) | |
| 650 | 4 | |a TransCelerate | |
| 650 | 4 | |a eSource | |
| 700 | 1 | |a Mehta, Prasann |e verfasserin |4 aut | |
| 700 | 1 | |a Vattikola, Arundhati |e verfasserin |4 aut | |
| 700 | 1 | |a Denney, Christine K |e verfasserin |4 aut | |
| 700 | 1 | |a Cherry, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Maniar, Rakesh M |e verfasserin |4 aut | |
| 700 | 1 | |a Kjaer, Jesper |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic innovation & regulatory science |d 2013 |g 54(2020), 5 vom: 03. Sept., Seite 1141-1151 |w (DE-627)NLM243752342 |x 2168-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2020 |g number:5 |g day:03 |g month:09 |g pages:1141-1151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43441-020-00138-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2020 |e 5 |b 03 |c 09 |h 1141-1151 | ||